Edition:
United Kingdom

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

3.45USD
15 Dec 2017
Change (% chg)

$0.02 (+0.58%)
Prev Close
$3.43
Open
$3.43
Day's High
$3.50
Day's Low
$3.25
Volume
11,513
Avg. Vol
8,787
52-wk High
$7.75
52-wk Low
$2.65

Chart for

About

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $32.35
Shares Outstanding(Mil.): 8.91
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Caladrius Biosciences reports 2017 third quarter results

* Q3 loss per share $0.38 from continuing operations Source text for Eikon: Further company coverage:

09 Nov 2017

BRIEF-Caladrius Biosciences files for resale of co's common stock‍​ by the selling stockholders

* Files for resale of up to 932,204 shares of Co's common stock‍​ by the selling stockholders - SEC filing Source text for Eikon: Further company coverage:

06 Sep 2017

BRIEF-Caladrius Biosciences Q2 loss per share $0.22 from continuing operations

* Q2 loss per share $0.22 from continuing operations Source text for Eikon: Further company coverage:

10 Aug 2017

Earnings vs. Estimates